A phase I study of PXD101 [belinostat] in combination with 17-AAG [tanespimycin] in advanced malignancies

Trial Profile

A phase I study of PXD101 [belinostat] in combination with 17-AAG [tanespimycin] in advanced malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Belinostat (Primary) ; Tanespimycin (Primary)
  • Indications Anaplastic large cell lymphoma; B cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoid leukaemia; Lymphoma; Mantle-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 15 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 03 Dec 2007 Status changed from initiated to completed.
    • 22 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top